glp-1/gip peptide Dual GLP-1 / GIP Receptor Agonist (CAS 2023788-19-2) Major physiological roles of GLP-1

The FTC's December 2025 enforcement action against NextMed was specifically about failure to disclose that an advertised telehealth price didn't include medication costs

These effects have been confirmed in animal experiments, but not in humans, and the specific mechanism remains unknown

Code 1130.52(a)(1)(b), 1130.61(4) and 1130.62(2) and (4)

This groundbreaking approval offers a needle-free alternative that delivers the powerful results of semaglutide in a convenient daily tablet.At Cape Fear Physical Medicine and Rehab, we are committed to staying at the forefront of obesity medicine

Medicare Part D coverage for GLP-1 weight loss medications is currently excluded, but CMS is exploring pilot programs that could begin as early as 2027

Schletter P, Beglinger C, Drewe J, et al